Shield Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Shield Therapeutics wird ein Gewinn- und Umsatzwachstum von 84.6% bzw. 46.9% pro Jahr prognostiziert, während der Gewinn pro Aktie um 104.1% pro Jahr wachsen soll.

Wichtige Informationen

84.6%

Wachstumsrate der Gewinne

104.1%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	19.6%
Wachstumsrate der Einnahmen	46.9%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	21 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Shield Therapeutics plc (LON:STX) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Oct 30

Shield Therapeutics (LON:STX) Is Making Moderate Use Of Debt

Oct 12

Shield Therapeutics plc's (LON:STX) Shares Leap 44% Yet They're Still Not Telling The Full Story

Aug 01

Increases to Shield Therapeutics plc's (LON:STX) CEO Compensation Might Cool off for now

Jun 13

Market Might Still Lack Some Conviction On Shield Therapeutics plc (LON:STX) Even After 35% Share Price Boost

May 22

Here's Why We're Watching Shield Therapeutics' (LON:STX) Cash Burn Situation

Mar 02

What Does The Future Hold For Shield Therapeutics plc (LON:STX)? These Analysts Have Been Cutting Their Estimates

May 06

Shield Therapeutics (LON:STX) Shareholders Have Enjoyed An Impressive 111% Share Price Gain

Mar 15

We're Interested To See How Shield Therapeutics (LON:STX) Uses Its Cash Hoard To Grow

Jan 27

Trade Alert: The CEO & Director Of Shield Therapeutics plc (LON:STX), Timothy Watts, Has Just Spent UK£70k Buying 22% More Shares

Dec 15

Gewinn- und Umsatzwachstumsprognosen

AIM:STX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	72	N/A	-6	-1	1
12/31/2025	54	-8	-7	-4	1
12/31/2024	29	-22	-17	-14	2
6/30/2024	21	-36	-23	-21	N/A
3/31/2024	17	-35	-32	-29	N/A
12/31/2023	13	-33	-40	-37	N/A
9/30/2023	10	-40	-35	-33	N/A
6/30/2023	7	-47	-30	-28	N/A
3/31/2023	6	-49	-28	-25	N/A
12/31/2022	5	-50	-25	-23	N/A
9/30/2022	5	-39	-27	-24	N/A
6/30/2022	4	-30	-31	-27	N/A
3/31/2022	3	-29	-29	-26	N/A
12/31/2021	2	-27	-27	-25	N/A
9/30/2021	2	-22	-21	-20	N/A
6/30/2021	3	-18	-16	-16	N/A
3/31/2021	9	-11	-9	-9	N/A
12/31/2020	14	-4	-2	-2	N/A
9/30/2020	13	-3	-1	-1	N/A
6/30/2020	11	-2	0	0	N/A
3/31/2020	6	-6	-4	-3	N/A
12/31/2019	1	-12	-7	-5	N/A
9/30/2019	8	-4	-1	1	N/A
6/30/2019	15	3	4	6	N/A
3/31/2019	15	0	0	3	N/A
12/31/2018	15	-2	-4	0	N/A
9/30/2018	8	-13	-14	-9	N/A
6/30/2018	1	-24	-24	-19	N/A
3/31/2018	1	-26	N/A	-21	N/A
12/31/2017	1	-26	N/A	-22	N/A
9/30/2017	1	-24	N/A	-21	N/A
6/30/2017	0	-21	N/A	-19	N/A
3/31/2017	0	-19	N/A	-16	N/A
12/31/2016	0	-19	N/A	-13	N/A
9/30/2016	0	-12	N/A	-12	N/A
6/30/2016	0	-4	N/A	-10	N/A
3/31/2016	0	-19	N/A	-8	N/A
12/31/2015	N/A	-35	N/A	-6	N/A
9/30/2015	0	-41	N/A	-5	N/A
6/30/2015	0	-49	N/A	-4	N/A
3/31/2015	0	-33	N/A	-5	N/A
12/31/2014	0	-20	N/A	-5	N/A
12/31/2013	0	-7	N/A	-5	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: STX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: STX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: STX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: STXDie Einnahmen des Unternehmens (46.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt UK (3.5% pro Jahr).

Hohe Wachstumseinnahmen: STXDie Einnahmen des Unternehmens (46.9% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von STX in 3 Jahren voraussichtlich hoch sein wird

Shield Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 88% to UK£0.30

No longer forecast to breakeven

Consensus estimates of losses per share improve by 46%

Consensus revenue estimates fall by 16%

Consensus estimates of losses per share improve by 11%

Consensus revenue estimates fall by 34%

Recent updates

Price target increased by 88% to UK£0.30

No longer forecast to breakeven

Consensus estimates of losses per share improve by 46%

Shield Therapeutics plc (LON:STX) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Shield Therapeutics (LON:STX) Is Making Moderate Use Of Debt

New minor risk - Profitability

Consensus revenue estimates fall by 16%

Shield Therapeutics plc Announces Health Canada Approves ACCRUFeR as Prescription Drug for the Treatment of Adults with Iron Deficiency Anemia

Shield Therapeutics plc to Report First Half, 2024 Results on Sep 04, 2024

Shield Therapeutics plc's (LON:STX) Shares Leap 44% Yet They're Still Not Telling The Full Story

Now 36% overvalued after recent price rise

Shield Therapeutics plc Announces CEO Changes

Consensus estimates of losses per share improve by 11%

Rudolf Widmann Joins Board of Shield Therapeutics plc as Non-Executive Director

Insufficient new directors

Increases to Shield Therapeutics plc's (LON:STX) CEO Compensation Might Cool off for now

Market Might Still Lack Some Conviction On Shield Therapeutics plc (LON:STX) Even After 35% Share Price Boost

Consensus revenue estimates fall by 34%

Price target increased by 700% to UK£0.16

Shield Therapeutics plc, Annual General Meeting, Jun 20, 2024

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Shield Therapeutics plc to Report Fiscal Year 2023 Final Results on May 10, 2024

Consensus revenue estimates decrease by 13%

Consensus revenue estimates fall by 19%

Shield Therapeutics plc to Report Fiscal Year 2023 Final Results on Apr 30, 2024

Consensus EPS estimates fall by 13%, revenue upgraded

Consensus EPS estimates fall by 13%, revenue upgraded

New major risk - Share price stability

Forecast to breakeven in 2025

Forecast to breakeven in 2025

Shield Therapeutics Appoints Santosh Shanbhag as New CFO, Effective January 16, 2024

Independent Non Executive Chairman recently bought UK£122k worth of stock

Consensus EPS estimates upgraded to US$0.036 loss

Consensus revenue estimates decrease by 11%

Shield Therapeutics plc Announces Hans-Peter Rudolf Is Standing Down from His Role as Chief Financial Officer on 20 October 2023

Shield Therapeutics plc has completed a Follow-on Equity Offering in the amount of £5.109782 million.

Consensus revenue estimates fall by 28%

First half 2023 earnings released: US$0.025 loss per share (vs US$0.069 loss in 1H 2022)

Shield Therapeutics plc has completed a Follow-on Equity Offering in the amount of £4.991445 million.

New major risk - Financial position

Price target decreased by 19% to UK£0.47

Shield Therapeutics plc to Report First Half, 2023 Results on Sep 28, 2023

Shield Therapeutics plc to Report First Half, 2023 Results on Sep 28, 2023

New major risk - Share price stability

Consensus EPS estimates upgraded to UK£0.034 loss, revenue downgraded

Shield Therapeutics plc, Annual General Meeting, Jun 28, 2023

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

Consensus estimates of losses per share improve by 13%

No longer forecast to breakeven

Shield Therapeutics plc Announces Regulatory Pathway and Timelines for Accrufer® Approval in the Republic of Korea

Shield Therapeutics plc Announces That Shelf-Life for Accrufer® Extended to 48 Months

No longer forecast to breakeven

First half 2022 earnings released: UK£0.05 loss per share (vs UK£0.04 loss in 1H 2021)

Shield Therapeutics plc to Report First Half, 2022 Results on Sep 08, 2022

Shield Therapeutics plc Announces New Drug Submission Accepted by Health Canada

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Shield Therapeutics plc, Annual General Meeting, Jul 27, 2022

Shield Therapeutics plc to Report Fiscal Year 2021 Results on Jun 30, 2022

Forecast breakeven date pushed back to 2024

Price target decreased to UK£2.00

Here's Why We're Watching Shield Therapeutics' (LON:STX) Cash Burn Situation

Executive Director Timothy Watts has left the company

First half 2021 earnings released: UK£0.04 loss per share (vs UK£0.027 profit in 1H 2020)

Consensus forecasts updated

Shield Therapeutics plc Confirms to Launch Accrufer® in the US on July 1, 2021

Shield Therapeutics (Stx): Accrufer Launch on Schedule

Consensus forecasts updated